National Defense Medical Center

Tsung-Chih Chen

Hsu-Shan Huang

Tai-Lung Cha

Dah-Shyong Yu

Yu-Ru Lee

Hsu-shan Huang

The invention provides a series of novel thiochromeno[2,3-c]quinolin-12-one derivatives. Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with treating effective amount are prepared into pharmaceutical compositions for inhibition of topoisomerase type I and II, inhibition of cancer cell growth, further treating cancer.

[object Object]

A heterocyclic fused anthraquinone derivative, which is represented by a formula (I): wherein Ris a substituent being one selected from a group consisting of hydrogen, halogens, aminoalkyl group, sulfoalkyl group, haloalkyl group, piperazino group, sulfonyl group, morpholino group, alkali group or one substituent represented by a formula (II): wherein Ris amino group, oxyl group or a thiol group. In the meantime, a method for manufacturing the above-mentioned heterocyclic fused anthraquinone derivatives and a pharmaceutical composition using thereof are also disclosed here.

Heterocyclic fused anthraquinone derivatives, manufacturing method and pharmaceutical composition using thereof

Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: and their pharmaceutically acceptable salts.

Growing community of inventors

Taipei, Taiwan

Tsung-Chih Chen